secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2024-01-10T23:59:59+00:00
Accession:  0001193125-24-005614
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seres reports preliminary Q4 VOWST net sales of $10.4M; FDA Fast Track for SER-155
--------------------------------------------------------------------------------

- VOWST Q4 2023 net sales approx $10.4M (unaudited); total 2023 net sales since June launch approx $19.6M.
- 2,833 patient enrollment forms received and 2,015 new patient starts since launch through year-end 2023.
- SER-155 received FDA Fast Track Designation; Phase 1b Cohort 2 data readout expected in Q3 2024.
- Preliminary cash, cash equivalents, and investments of approx $128M as of Dec 31, 2023.
- Company expects cash plus expected $45M Tranche B from Oaktree to support operations into Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312524005614/0001193125-24-005614-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312524005614/d129973d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-005614

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer